Drugs / Setmelanotide

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (3) US (FDA) IMCIVREE 2022-06-16 – 2026-03-19 fda.gov
Approved EU (EMA) Imcivree 2021-07-16 europa.eu
Approved US (FDA) IMCIVREE 2020-11-25 fda.gov

Trials 23 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04348175 Jul 2020 → Apr 2021 impaired renal function disease Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 29 trials
Phase 2 NCT07496463 Apr → Oct 2026 expected obesity disorder, pseudohypoparathyroidism type 1A Massachusetts General Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06772597 Mar 2025 → Oct 2026 expected Prader-Willi syndrome, obesity disorder Rhythm Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase 2 NCT04963231 Nov 2021 → Aug 2023 inherited obesity Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT04725240 Jun 2021 → Jun 2022 acquired hypothalamic obesity Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT03262610 Aug 2017 → Jan 2018 hypertriglyceridemia, obesity disorder Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT03013543 Feb 2017 → Mar 2022 obesity due to melanocortin 4 receptor deficiency Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT02311673 Mar 2015 → Oct 2016 Prader-Willi syndrome Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT02507492 Jan 2015 → Jan 2018 inherited obesity Charite University, Berlin, Germany Unknown No outcome recorded
Phase 2 NCT01749137 Jan → Sep 2013 obesity disorder Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03651765 Jul 2018 → Jan 2025 inherited obesity Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 39 trials
Phase 3 NCT06760546 Sep 2025 → Mar 2027 expected acquired hypothalamic obesity, isolated optic nerve hypoplasia, non-acquired combined pituitary hormone deficiency, pituitary stalk interruption syndrome +1 Rhythm Pharmaceuticals, Inc. Recruiting No outcome recorded
Phase 3 NCT06596135 Oct 2024 → Jun 2026 inherited obesity Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 3 NCT05774756 Apr 2023 → Mar 2025 overdue acquired hypothalamic obesity Rhythm Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase 3 NCT04966741 Mar 2022 → Sep 2023 Bardet-Biedl syndrome, obesity due to leptin receptor gene deficiency, obesity due to pro-opiomelanocortin deficiency, obesity due to prohormone convertase I deficiency Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 3 NCT05194124 Dec 2021 → Oct 2023 Bardet-Biedl syndrome, obesity due to pro-opiomelanocortin deficiency Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 3 NCT05093634 Dec 2021 → Dec 2025 overdue inherited obesity Rhythm Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase 3 NCT03746522 Nov 2018 → Nov 2020 Alstrom syndrome, Bardet-Biedl syndrome Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 3 NCT03287960 Jan 2018 → Sep 2020 obesity due to leptin receptor gene deficiency Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 3 NCT02896192 Feb 2017 → May 2020 obesity due to pro-opiomelanocortin deficiency Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 42 trials
Phase 4 NCT07674290 Jan 2023 → Dec 2030 expected Alstrom syndrome, Bardet-Biedl syndrome Tom Hühne Recruiting No outcome recorded
Phase 4 NCT05046132 Aug 2021 → Apr 2022 Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase not stated1 trial
NCT05183802 Bardet-Biedl syndrome, obesity disorder Rhythm Pharmaceuticals, Inc. Approved for marketing No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01867437 Comparator May 2013 → Mar 2014 morbid obesity Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1 NCT02431442 Comparator Jan 2012 → Jan 2014 obesity disorder Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02041195 Comparator Jan → Aug 2014 morbid obesity Rhythm Pharmaceuticals, Inc. Completed No outcome recorded
Phase 41 trial
Phase 4 NCT05812183 Background Jul 2023 → Feb 2025 University of California, Los Angeles Withdrawn No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 29 sources stand behind the page.

FieldValueCited text
Known as Setmelanotide Setmelanotide (Imcivree)” NCT05812183
23

NCT04725240

NCT03746522

NCT01749137

NCT03013543

NCT02896192

NCT06772597

NCT05046132

NCT04963231

NCT06596135

NCT04348175

NCT06760546

NCT03651765

NCT05183802

NCT02041195

NCT07674290

NCT05774756

NCT03262610

NCT05194124

NCT04966741

NCT05093634

NCT07496463

NCT03287960

NCT02311673

Known as BIM-22493 ChEMBL registry synonym — accepted as the source's own label CHEMBL3301624
Known as Imcivree “Setmelanotide (Imcivree)” NCT05812183
Known as RM-493 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02507492
2

NCT02431442

NCT01867437

Known as RM-493 ACETATE ChEMBL registry synonym — accepted as the source's own label CHEMBL3301624
Known as Setmelanotida ChEMBL registry synonym — accepted as the source's own label CHEMBL3301624
Known as SETMELANOTIDE ACETATE ChEMBL registry synonym — accepted as the source's own label CHEMBL3301624
Action Activate “a Melanocortin 4 Receptor (MC4R) Agonist” NCT02311673
Modality Peptide “RM-493 is a potent, selective peptide agonist for the MC4R” NCT01867437
Modality Protein / enzyme biologic CHEMBL3301624
Route Subcutaneous “RM-493 (1 mg/24 h) or placebo by continuous subcutaneous infusion over 72 hours” PMID 25675384 Feb 2015
Target MC4R “RM-493 is a potent, selective peptide agonist for the MC4RNCT01867437